Evidence map›Paper›PMID 30517150›Full record

ArticlePloS one2018

Hypervirulent group A Streptococcus emergence in an acaspular background is associated with marked remodeling of the bacterial cell surface.

Jessica Galloway-Peña, Sruti DebRoy, Chelcy Brumlow, Xiqi Li, Truc T Tran, Nicola Horstmann, Hui Yao, Ken Chen, Fang Wang, Bih-Fang Pan and 8 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Antibiotics (Basel, Switzerland) · 2023
    Article
  2. Article
  3. Article
  4. Article
  5. Population Genomics ofmSystems · 2021
    Article
  6. Novel Technologies in Studying Brain Immune Response.Oxidative medicine and cellular longevity · 2021
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. To be capsulated or not be capsulated: that is the GAS question.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019
    Article
  12. ModelingFrontiers in cellular and infection microbiology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Jessica Galloway-PeñaDepartment of Infectious Diseases Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.ORCID 0000-0003-1081-254X
Sruti DebRoyDepartment of Infectious Diseases Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Chelcy BrumlowDepartment of Infectious Diseases Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.ORCID 0000-0002-5766-7637
Xiqi LiDepartment of Infectious Diseases Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Truc T TranCenter for Antimicrobial Resistance and Microbial Genomics and Division of Infectious Diseases, UTHealth McGovern Medical School, Houston, Texas, United States of America.
Nicola HorstmannDepartment of Infectious Diseases Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.ORCID 0000-0002-3620-5169
Hui YaoDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Ken ChenDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.ORCID 0000-0003-4013-5279
Fang WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Bih-Fang PanThe Proteomics and Metabolomics Facility, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.ORCID 0000-0002-6382-6200
David H HawkeThe Proteomics and Metabolomics Facility, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.ORCID 0000-0002-6102-7843
Erika J ThompsonDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Cesar A AriasCenter for Antimicrobial Resistance and Microbial Genomics and Division of Infectious Diseases, UTHealth McGovern Medical School, Houston, Texas, United States of America.
Vance G FowlerDivision of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, United States of America.
Micah M BhattiDepartment of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Awdhesh KaliaGraduate Program in Diagnostic Genetics, School of Health Professions, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Anthony R FloresCenter for Antimicrobial Resistance and Microbial Genomics and Division of Infectious Diseases, UTHealth McGovern Medical School, Houston, Texas, United States of America.ORCID 0000-0002-6402-4269
Samuel A ShelburneDepartment of Infectious Diseases Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.ORCID 0000-0001-9721-263X
The University of Texas MD Anderson Cancer Center · USThe University of Texas Health Science Center at Houston · USDuke Medical Center · USUniversidad El Bosque · CO

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
The LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7M
Role of response regulator phosphorylation in group A streptococcal pathogenesisR01AI125292 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHELBURNE, SAMUEL A · 2017 to 2021
$2.0M
POR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5M
Pharmacokinetics and metabolomics of vitamin D supplementation in critical illnessR01GM115774 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI CHRISTOPHER, KENNETH BRUCE · 2016 to 2018
$940k
Orbitrap Elite High-Resolution Mass Spectrometer for Proteomics and MetabolomicsS10OD012304 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HAWKE, DAVID H · 2013 to 2013
$877k
Data commons for 'omic, microscopy and analysis core facilitiesS10OD018164 · OD · DUKE UNIVERSITY · PI WRAY, GREGORY A. · 2014 to 2014
$598k
Novel mechanisms of emergence of hypervirulent group A StreptococcusR21AI132920 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHELBURNE, SAMUEL A · 2018 to 2019
$440k
PLURIPOTENT STEM CELL-BASED IMMUNOTHERAPIESR21AI132910 · NIAID · UNIVERSITY OF ARIZONA · PI BHATTACHARYA, DEEPTA · 2018 to 2019
$435k
NCI NIH HHS P30 CA016672NIAID NIH HHS K24 AI121296NIAID NIH HHS R01 AI125292NIAID NIH HHS R01 AI134637NIAID NIH HHS R21 AI132910NIAID NIH HHS R21 AI132920NIGMS NIH HHS R01 GM115774NIH HHS S10 OD012304NIH HHS S10 OD018164
6 · The paper itself

Abstract

Inactivating mutations in the control of virulence two-component regulatory system (covRS) often account for the hypervirulent phenotype in severe, invasive group A streptococcal (GAS) infections. As CovR represses production of the anti-phagocytic hyaluronic acid capsule, high level capsule production is generally considered critical to the hypervirulent phenotype induced by CovRS inactivation. There have recently been large outbreaks of GAS strains lacking capsule, but there are currently no data on the virulence of covRS-mutated, acapsular strains in vivo. We investigated the impact of CovRS inactivation in acapsular serotype M4 strains using a wild-type (M4-SC-1) and a naturally-occurring CovS-inactivated strain (M4-LC-1) that contains an 11bp covS insertion. M4-LC-1 was significantly more virulent in a mouse bacteremia model but caused smaller lesions in a subcutaneous mouse model. Over 10% of the genome showed significantly different transcript levels in M4-LC-1 vs. M4-SC-1 strain. Notably, the Mga regulon and multiple cell surface protein-encoding genes were strongly upregulated-a finding not observed for CovS-inactivated, encapsulated M1 or M3 GAS strains. Consistent with the transcriptomic data, transmission electron microscopy revealed markedly altered cell surface morphology of M4-LC-1 compared to M4-SC-1. Insertional inactivation of covS in M4-SC-1 recapitulated the transcriptome and cell surface morphology. Analysis of the cell surface following CovS-inactivation revealed that the upregulated proteins were part of the Mga regulon. Inactivation of mga in M4-LC-1 reduced transcript levels of multiple cell surface proteins and reversed the cell surface alterations consistent with the effect of CovS inactivation on cell surface composition being mediated by Mga. CovRS-inactivating mutations were detected in 20% of current invasive serotype M4 strains in the United States. Thus, we discovered that hypervirulent M4 GAS strains with covRS mutations can arise in an acapsular background and that such hypervirulence is associated with profound alteration of the cell surface.

Indexed as

AnimalsBacterial CapsulesBacterial ProteinsCell MembraneFemaleGenes, BacterialHistidine KinaseHumansIntracellular Signaling Peptides and ProteinsMiceMicroscopy, Electron, TransmissionMutationRegulonRepressor ProteinsSerogroupStreptococcal InfectionsBacterial ProteinsCovS protein, Streptococcus pyogenesCsrR protein, Streptococcus pyogenesHistidine KinaseIntracellular Signaling Peptides and ProteinsRepressor Proteins

Identifiers

PMID30517150
PMCPMC6281247
OpenAlexW2903239974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.